Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G. Raje N, et al. Among authors: willenbacher w. J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5. J Med Econ. 2018. PMID: 29480139 Free article. Clinical Trial.
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Raje N, et al. Among authors: willenbacher w. Blood Cancer J. 2016 Jan 8;6(1):e378. doi: 10.1038/bcj.2015.96. Blood Cancer J. 2016. PMID: 26745852 Free PMC article. Clinical Trial.
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD. Raje N, et al. Among authors: willenbacher w. Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9. Lancet Oncol. 2018. PMID: 29429912 Clinical Trial.
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Buske C, et al. Among authors: willenbacher w. Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Lancet Haematol. 2018. PMID: 29958569 Review.
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Mohty M, et al. Among authors: willenbacher w. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30030033 Free article.
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W. Terpos E, et al. Among authors: willenbacher w. J Med Econ. 2019 Aug;22(8):766-776. doi: 10.1080/13696998.2019.1606002. Epub 2019 Apr 29. J Med Econ. 2019. PMID: 30969797 Free article.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: willenbacher w. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Willenbacher W, Thangavadivel S, Greil R, Willenbacher E, Weger R, Manzl C, Jöhrer K, Brunner A. Willenbacher W, et al. Among authors: willenbacher e. Leuk Lymphoma. 2016 Oct;57(10):2330-41. doi: 10.3109/10428194.2016.1144880. Epub 2016 Feb 16. Leuk Lymphoma. 2016. PMID: 26880040
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W; Austrian Myeloma Registry (AMR). Willenbacher E, et al. Among authors: willenbacher w. PLoS One. 2016 Mar 3;11(3):e0147381. doi: 10.1371/journal.pone.0147381. eCollection 2016. PLoS One. 2016. PMID: 26937956 Free PMC article.
91 results